BOLD Boundless Bio, Inc. - Common Stock
$2.92
价格 · 八月 19, 2026
截至...的财报数据 八月 7, 2026
关于 Boundless Bio, Inc. - Common Stock 公司概况（来自维基百科）
BOLD 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$2.92
市值
$65M
P/E (TTM)
-1.1
每股收益 (TTM)
$-2.60
营收 (TTM)
—
股息收益率
—
ROE
-46.7%
负债/权益
—
52周区间
$1 – $3
BOLD 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
—
EPS
$-2.60
2023-12-31
→
2025-12-31
自由现金流
$-47M
2024-12-31
→
2025-12-31
利润率
—
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
BOLD
同行中位数
P/E (TTM)
-1.1
—
P/B (市净率)
0.7
1.6
Price / FCF (股价/自由现金流)
-1.4
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
BOLD
同行中位数
ROA
-32.0%
-64.3%
ROE
-46.7%
-102.1%
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
BOLD
同行中位数
Current Ratio (流动比率)
8.7
4.8
Quick Ratio (速动比率)
8.6
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
BOLD
同行中位数
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
BOLD
同行中位数
BOLD 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
卖出
6 位分析师
- 强烈买入 0 0.0%
- 买入 0 0.0%
- 持有 3 50.0%
- 卖出 1 16.7%
- 强烈卖出 2 33.3%
12个月价格目标
1 位分析师 · 2026-08-19
最低
$4.00
最高
$4.00
中位数目标
$4.00
+37.2%
平均目标
$4.00
+37.2%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.07%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-1.06 | $-0.59 | -0.47% |
| 2026年3月31日 | $-0.60 | $-0.59 | -0.01% |
| 2025年12月31日 | $-0.58 | $-0.53 | -0.05% |
| 2025年9月30日 | $-0.62 | $-0.59 | -0.03% |
| 2025年6月30日 | $-0.70 | $-0.66 | -0.04% |
| 2025年3月31日 | $-0.71 | $-0.75 | 0.04% |
| 2024年12月31日 | $-0.74 | $-0.78 | 0.04% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| BOLD | $27M | -0.5 | — | — | -46.7% | — |
| XBIT | — | -1.6 | — | — | — | — |
| TENX | $114M | -9.1 | — | — | -52.5% | — |
| PMVP | $67M | -0.8 | -40.5% | -1226.8% | -63.4% | — |
| MNOV | $64M | -5.5 | — | -2928.8% | -27.1% | — |
| HRTX | $245M | -10.8 | 7.4% | -13.0% | 312.5% | 73.3% |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | — |
| EXOZ | $92M | -10.0 | — | — | -172.3% | — |
| INKT | — | -3.8 | 4.5% | -6931.8% | 63.4% | — |
| CLNN | $64M | — | -41.5% | -13086.5% | 200.2% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 13
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $45M | $55M | $43M | |
| SG&A Expense | $19M | $18M | $12M | |
| Operating Expenses | $64M | $73M | $55M | |
| Operating Income | $-64M | $-73M | $-55M | |
| Interest Income | $5M | $8M | $5M | |
| Other Non-op | $-2.0K | $12.0K | $80.0K | |
| Income Tax | $0 | $0 | · | |
| Net Income | $-58M | $-65M | $-49M | |
| EPS (Basic) | $-2.60 | $-3.85 | $-40.65 | |
| EPS (Diluted) | $-2.60 | $-3.85 | $-40.65 | |
| Shares (Basic) | 22,360,000 | 16,984,000 | 1,216,000 | |
| Shares (Diluted) | 22,360,000 | 16,984,000 | 1,216,000 | |
| EBITDA | $-62M | $-72M | · |
资产负债表 19
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $18M | $27M | $24M | |
| Short-term Investments | $90M | $126M | $97M | |
| Prepaid Expense | $2M | $2M | $3M | |
| Current Assets | $110M | $154M | $124M | |
| PP&E (Net) | $3M | $4M | $3M | |
| PP&E (Gross) | $8M | $8M | $5M | |
| Accum. Depreciation | $5M | $4M | $3M | |
| Total Assets | $157M | $206M | $130M | |
| Accounts Payable | $1M | $1M | $2M | |
| Current Liabilities | $13M | $8M | $9M | |
| Capital Leases | $46M | $48M | · | |
| Total Liabilities | $58M | $56M | $9M | |
| Common Stock | $2.0K | $2.0K | $0 | |
| Paid-in Capital | $358M | $352M | $9M | |
| Retained Earnings | $-260M | $-201M | $-136M | |
| AOCI | $64.0K | $121.0K | $40.0K | |
| Stockholders' Equity | $99M | $151M | $-127M | |
| Liabilities + Equity | $157M | $206M | $130M | |
| Shares Outstanding | 22,407,000 | 22,300,000 | 1,248 |
现金流 10
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| D&A | $1M | $1M | $957.0K | |
| Stock-based Comp | $6M | $8M | $3M | |
| Deferred Tax | $0 | · | · | |
| Other Non-cash | $4M | $-4M | · | |
| Operating Cash Flow | $-47M | $-61M | $-47M | |
| CapEx | $546.0K | $3M | $633.0K | |
| Investing Cash Flow | $38M | $-26M | $-38M | |
| Financing Cash Flow | $141.0K | $90M | $98M | |
| Net Change in Cash | $-9M | $3M | $13M | |
| Free Cash Flow | $-47M | $-63M | · |
盈利能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ROA | -32.0% | -38.9% | · | |
| ROE | -46.7% | -554.9% | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 8.7 | 19.0 | · | |
| Quick Ratio | 8.6 | 18.7 | · |
估值 (TTM) 8
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net Income TTM | $-58M | $-65M | · | |
| Market Cap | $27M | $64.7K | · | |
| P/E | -0.5 | -0.8 | · | |
| P/B | 0.3 | 0.0 | · | |
| P / Tangible Book | 0.3 | 0.0 | · | |
| P / Cash Flow | -0.6 | -0.0 | · | |
| P / FCF | -0.6 | -0.0 | · | |
| Earnings Yield | -216.7% | -132.8% | · |
损益表 12
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $14M | $10M | $10M | $11M | $12M | $12M | $13M | $14M | $15M | $13M | $10M | |
| SG&A Expense | $10M | $5M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $3M | |
| Operating Expenses | $24M | $14M | $14M | $15M | $17M | $17M | $18M | $19M | $19M | $17M | $14M | |
| Operating Income | $-24M | $-14M | $-14M | $-15M | $-17M | $-17M | $-18M | $-19M | $-19M | $-17M | $-14M | |
| Interest Income | $690.0K | $920.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $2M | |
| Other Non-op | $1.0K | · | $0 | $0 | $0 | $-2.0K | $-85.0K | $32.0K | $33.0K | $32.0K | $64.0K | |
| Net Income | $-24M | $-14M | $-13M | $-14M | $-16M | $-16M | $-16M | $-17M | $-17M | $-15M | $-12M | |
| EPS (Basic) | $-1.06 | $-0.60 | $-0.57 | $-0.62 | $-0.70 | $-0.71 | $9.93 | $-0.74 | $-0.77 | $-12.27 | $-9.75 | |
| EPS (Diluted) | $-1.06 | $-0.60 | $-0.57 | $-0.62 | $-0.70 | $-0.71 | $9.93 | $-0.74 | $-0.77 | $-12.27 | $-9.75 | |
| Shares (Basic) | 22,450,000 | 22,407,000 | -44,682,000 | 22,386,000 | 22,356,000 | 22,300,000 | -28,551,000 | 22,254,000 | 22,023,000 | 1,258,000 | -2,403,000 | |
| Shares (Diluted) | 22,450,000 | 22,407,000 | -44,682,000 | 22,386,000 | 22,356,000 | 22,300,000 | -28,551,000 | 22,254,000 | 22,023,000 | 1,258,000 | -2,403,000 | |
| EBITDA | $-24M | $-14M | · | $-15M | $-17M | $-17M | · | $-19M | $-19M | $-17M | · |
资产负债表 19
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20M | $17M | $18M | $15M | $15M | $15M | $27M | $40M | $31M | $25M | $24M | |
| Short-term Investments | $52M | $75M | $90M | $103M | $112M | $123M | $126M | $127M | $148M | $80M | $97M | |
| Prepaid Expense | $1M | $2M | $2M | $3M | $3M | $2M | $2M | $3M | $4M | $7M | $3M | |
| Current Assets | $74M | $95M | $110M | $120M | $130M | $140M | $154M | $170M | $183M | $112M | $124M | |
| PP&E (Net) | $97.0K | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $2M | $3M | |
| PP&E (Gross) | $4M | $8M | $8M | $8M | $8M | $8M | $8M | $7M | $7M | $5M | $5M | |
| Accum. Depreciation | $3M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | |
| Total Assets | $74M | $141M | $157M | $169M | $179M | $191M | $206M | $175M | $188M | $117M | $130M | |
| Accounts Payable | $1M | $2M | $1M | $1M | $2M | $1M | $1M | $3M | $2M | $3M | $2M | |
| Current Liabilities | $8M | $10M | $13M | $12M | $9M | $6M | $8M | $10M | $9M | $11M | $9M | |
| Capital Leases | $0 | $45M | $46M | $47M | $48M | $48M | $48M | · | · | · | · | |
| Total Liabilities | $8M | $55M | $58M | $59M | $57M | $55M | $56M | · | · | · | $9M | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $0 | |
| Paid-in Capital | $363M | $360M | $358M | $357M | $356M | $354M | $352M | $350M | $348M | $10M | $9M | |
| Retained Earnings | $-297M | $-273M | $-260M | $-247M | $-233M | $-217M | $-201M | $-185M | $-169M | $-152M | $-136M | |
| AOCI | $-32.0K | $-23.0K | $64.0K | $50.0K | $-4.0K | $32.0K | $121.0K | $236.0K | $-64.0K | $-21.0K | $40.0K | |
| Stockholders' Equity | $66M | $86M | $99M | $110M | $123M | $137M | $151M | $165M | $179M | $-141M | $-127M | |
| Liabilities + Equity | $74M | $141M | $157M | $169M | $179M | $191M | $206M | $175M | $188M | $117M | $130M | |
| Shares Outstanding | 22,475,000 | 22,407,000 | 22,407,000 | 22,386,000 | 22,386,000 | 22,300,000 | 22,300,000 | 22,254,465 | 22,254,102 | 1,262,638 | 1,248 |
现金流 9
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $284.0K | $307.0K | $310.0K | $317.0K | $317.0K | $296.0K | $262.0K | $265.0K | $263.0K | $247.0K | |
| Stock-based Comp | $3M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $911.0K | |
| Other Non-cash | · | $-3M | · | · | · | $-886.0K | · | · | · | · | · | |
| Operating Cash Flow | $-21M | $-15M | $-10M | $-10M | $-12M | $-15M | $-16M | $-13M | $-16M | $-16M | $-12M | |
| CapEx | $38.0K | $8.0K | $424.0K | $15.0K | $48.0K | $59.0K | $466.0K | $483.0K | $2M | $83.0K | $268.0K | |
| Investing Cash Flow | $23M | $15M | $13M | $10M | $11M | $3M | $2M | $22M | $-68M | $18M | $16M | |
| Financing Cash Flow | · | · | $24.0K | $0 | · | · | $113.0K | $-13.0K | $91M | $-924.0K | $-1M | |
| Net Change in Cash | $2M | $-385.0K | $3M | $283.0K | $-420.0K | $-11M | $-14M | $9M | $6M | $1M | $3M | |
| Free Cash Flow | · | $-15M | · | · | · | $-15M | · | · | · | $-16M | · |
盈利能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -18.7% | -8.2% | · | -8.1% | -8.5% | -10.2% | · | -18.9% | -18.0% | -26.4% | · | |
| ROE | -25.1% | -12.2% | · | -10.1% | -10.4% | 686.3% | · | -20.0% | -18.9% | 21.9% | · |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.5 | 9.9 | · | 10.1 | 14.1 | 22.1 | · | 17.0 | 20.4 | 10.5 | · | |
| Quick Ratio | 9.3 | 9.7 | · | 9.9 | 13.8 | 21.8 | · | 16.7 | 20.0 | 9.9 | · |
估值 (TTM) 8
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-67M | $-59M | · | $-62M | $-65M | $-65M | · | $-62M | $-58M | $-53M | · | |
| Market Cap | $56M | $25M | · | $28M | $23M | $34M | · | $77M | $86M | $18M | · | |
| P/E | -0.8 | -0.4 | · | -0.4 | -0.3 | -0.1 | · | -0.1 | -0.1 | -0.3 | · | |
| P/B | 0.9 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.5 | 0.5 | -0.1 | · | |
| P / Tangible Book | 0.9 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.5 | 0.5 | · | · | |
| P / Cash Flow | · | -1.6 | · | · | · | -2.3 | · | · | · | -1.1 | · | |
| P / FCF | · | -1.6 | · | · | · | -2.3 | · | · | · | -1.1 | · | |
| Earnings Yield | -119.2% | -239.1% | · | -225.2% | -289.1% | -959.6% | · | -705.8% | -879.3% | -302.9% | · |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| 净收入 | $-58M | $-65M | $-49M |
| 稀释后每股收益 (EPS) | $-2.60 | $-3.85 | $-40.65 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| 流动比率 | 8.7 | 19.0 | — |
| 速动比率 | 8.6 | 18.7 | — |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| 自由现金流 | $-47M | $-63M | — |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 45 家申报者 · $37.6M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 16 (+12 与上一季度对比) | 7 (+1 与上一季度对比) | 8 (+2 与上一季度对比) | 10 (+2 与上一季度对比) | +8.0M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 14 位内幕人士 · 8 位高管 · 7 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Zachary Hornby | President & CEO | 2026年1月23日 A | — | 0 | 0 | $0 |
| Jami Rubin | Chief Financial Officer | 2024年8月19日 A | — | 0 | 0 | $0 |
| Robert Doebele | Chief Medical Officer | 2026年1月23日 A | — | 0 | 0 | $0 |
| Jessica Oien | Chief Legal Officer and Corporate Secretary | 2026年1月23日 A | — | 0 | 0 | $0 |
| Christian Hassig | Chief Scientific Officer | 2026年1月23日 A | — | 0 | 0 | $0 |
| David A Hinkle | Senior VP, Finance, Controller and Treasurer | 2026年1月23日 A | — | 0 | 0 | $0 |
| Klaus W. Wagner | Chief Medical Officer | 2024年8月19日 A | — | 0 | 0 | $0 |
| Neil Abdollahian | Chief Business Officer | 2024年8月19日 A | — | 0 | 0 | $0 |
| James Christensen | 董事 | 2026年6月15日 A | — | 0 | 0 | $0 |
| Nancy Whiting | 董事 | 2026年6月15日 A | — | 0 | 0 | $0 |
| Jennifer Lew | 董事 | 2026年6月15日 A | — | 0 | 0 | $0 |
| Jonathan E Lim | 董事 | 2026年6月15日 A | 550915 | 0 | 0 | $0 |
| Christine Brennan | 董事 | 2025年6月23日 A | — | 0 | 0 | $0 |
| Kristina Burow | 董事 | 2025年6月23日 A | 1181766 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC, Robert Nelsen, Keith Crandell, Clinton Bybee, Kristina Burow, Steven Gillis | 2024年10月29日 | — | 初始申报 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 3 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。